Sold as Metastron. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Strontium Chloride Sr-89 (sold as Metastron), first approved Jun 18, 1993, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| TriCalm Hydrogel® in the Treatment of Immunotherapy-Related PruritusImmunotherapy-related Pruritus · University of California, San Diego | Phase 2 | Recruiting | Dec 27, 2024 |
| Jun 18, 1993 | MetastronNDA 20134 · New molecular entity | Q Biomed | 7 | Marketed |
| Jan 6, 2003 | Strontium Chloride Sr-89ANDA 75941 | Q Biomed | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
